好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Prone Position and SUDEP
Epilepsy
P03 - (-)
133
BACKGROUND: Sudden unexpected death in epilepsy (SUDEP) is the primary cause of mortality among people with epilepsy. While the prone body position has been mentioned as a potential risk factor for SUDEP, the frequency of this position among SUDEP patients has not been analyzed on a large scale. We present the first meta-analysis to specifically evaluate the frequency of prone body position among a large number of SUDEP cases whose body position was known at the time of death.
DESIGN/METHODS: The study was conducted as a meta-analysis, based on a Pub-Med search performed on 9/11/12, using keywords 'SUDEP' OR 'Sudden unexpected death in epilepsy' OR 'Sudden unexplained death syndrome in epilepsy'. This search resulted in 517 publications meeting this criterion, of which 201 cases from 28 publications described at least one SUDEP case in which the body position was known at the time of death. Four other well-known video-EEG recorded SUDEP cases not appearing in the search were added to the meta-analysis.
RESULTS: Of the 205 SUDEP cases, 143 (69.8%) were found in the prone position, 17 (8.29%) were in the supine position, 23 (11.2%) were found in another position (defined as sitting or lateral), and 22 (10.7%) were in a position other than prone at the time of death. 82 of 205 deaths were reported as either witnessed or unwitnessed. Only 6 (7.32%) deaths were witnessed, compared to 76 (92.7%) unwitnessed cases. The scene of death was known in 98 cases. Of these, 69 (70.4%) were in bed; the remaining 29 cases were elsewhere.
CONCLUSIONS: There is a significant association between the prone body position and SUDEP. This finding indicates that the prone body position is an important risk factor for SUDEP.
Authors/Disclosures
Jennifer Liebenthal, MD (University of Kansas Medical Center)
PRESENTER 		No disclosure on file
James X. Tao, MD, PhD Dr. Tao has nothing to disclose.
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine) Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has or had stock in Biohaven.Dr. Lipton has or had stock in Manistee.Dr. Lipton has or had stock in Axon.Dr. Lipton has or had stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.